[144] Pediatrix Medical Group, Inc. SEC Filing

Rhea-AI Filing Summary

MD filed a Form 144 notice covering a planned sale of common stock. The filing states an intent to sell 10,478 common shares, with an aggregate market value of $240,994, on the NYSE, with an approximate sale date of 11/17/2025. The filing reports that these shares were acquired through stock plan activity from the issuer on several dates in 2021 and 2022. It also notes that total shares of the same class outstanding are 85,877,386. The signer represents that they are not aware of any material adverse, nonpublic information about the issuer’s operations.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Robert W. Baird 777 E. Wisconsin Ave. Milwaukee WI 53202	10478	240994	85877386	11/17/2025	NYSE

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	03/01/2021	Stock Plan Activity	Issuer			1573	03/01/2021	n/a
Common	05/16/2021	Stock Plan Activity	Issuer			2448	05/16/2021	n/a
Common	03/01/2022	Stock Plan Activity	Issuer			1572	03/01/2022	n/a
Common	05/12/2022	Stock Plan Activity	Issuer			4885	05/12/2022	n/a

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does MD's Form 144 filing report?

The Form 144 for MD reports a planned sale of 10,478 common shares with an aggregate market value of $240,994, to be sold on the NYSE.

How many MD shares are planned to be sold and on which exchange?

The notice covers the planned sale of 10,478 common shares of MD on the NYSE, with an approximate sale date of 11/17/2025.

How were the MD shares in this Form 144 acquired?

The shares were acquired through stock plan activity from the issuer on several dates, including 03/01/2021, 05/16/2021, 03/01/2022, and 05/12/2022, in blocks such as 1,573, 2,448, 1,572, and 4,885 shares.

How many MD common shares are outstanding according to this notice?

The filing states that the number of common shares outstanding is 85,877,386.

Does the person filing the MD Form 144 claim to have any undisclosed negative information?

The signer represents that they do not know any material adverse information about the issuer’s current or prospective operations that has not been publicly disclosed.

What time period of prior sales does the MD Form 144 reference?

The form calls for disclosure of all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold, though no specific sales are listed in the provided excerpt.